PART 1: GLP-1 Medications — What They Are and What They Actually Do
This is Part 1 of two. Part 2 covers what good care looks like when you're on one of these medications, and how to recognize when you're not getting it.
In my last post, on peptides, I promised a full deep dive on GLP-1s. This is it.
These medications are the most talked-about development in health right now, and one of the most misunderstood. There is real hope wrapped up in them and real confusion, big promises and big fears, and sorting out what's actually true has become genuinely difficult.
I'm not a prescriber, and I'm not going to tell you whether to take one. What I can do, after spending months with the research, is lay out what these drugs are, what they do, what they can't do, and who they aren't for — clearly enough that you can make your own decisions from real information instead of from headlines or a comment section.
That's the whole point. Not fear. Not a sales pitch. Just the truth, as clearly as I can give it.
What a GLP-1 actually is
GLP-1 stands for glucagon-like peptide-1. It's a hormone your own gut makes every time you eat. You made some this morning.
It does several jobs at once. It tells your pancreas to release insulin when your blood sugar rises. It tells your brain you've had enough. And it slows down how quickly food leaves your stomach.
This is ordinary human physiology. It has been happening in your body your entire life.
Which means the common worry that these medications are "unnatural chemicals" has it backwards. Ozempic, Wegovy, Mounjaro, Zepbound — they are engineered copies of a hormone you already produce. That's what the word agonist means when you see them called GLP-1 receptor agonists: something that switches on the same receptors your own hormone switches on. Your body cannot tell the difference between the medication and the real thing.
Why the medication is so much stronger than your own hormone
If the drug is just a copy of something you already make, it's fair to ask why it's so powerful.
The answer is time. Your natural GLP-1 barely lasts. Your gut releases it after a meal and an enzyme called DPP-4 breaks it down within about two minutes. A quick pulse, and it's gone.
The medications are built to survive that enzyme. Instead of two minutes, they last for days — most are a single injection once a week. That endurance is the entire difference between a hormone and a medication.
This also explains something worth knowing if you've been shopping for supplements. There is no such thing as a GLP-1 booster. You'll see products marketed as "nature's Ozempic," promising to raise your body's own GLP-1. Even if one of them does exactly that, the GLP-1 it raises still disappears in two minutes, the same as always. No supplement turns a two-minute hormone into a week-long medication.
Protein, fiber, and exercise genuinely do stimulate your natural GLP-1, and they're worth doing for your health. That's real. It is simply a different thing than the drug, and anything sold as an equivalent is selling you a story.
These are not new drugs
It's easy to assume these appeared out of nowhere around 2022, because that's when they took over the culture. They didn't. This class of medication has been in use for about twenty years.
The origin is one of my favorite stories in medicine. In 1992, an endocrinologist named Dr. John Eng, working at a VA hospital in the Bronx, was studying the venom of the Gila monster — a large desert lizard that can go months between meals. In it he found a compound called exendin-4 that acts on the same receptors as human GLP-1, with one crucial difference: it naturally resists the enzyme that destroys ours in minutes. It lasted for hours instead.
That compound became the first GLP-1 medication, approved by the FDA in April 2005. To be precise, the lizard peptide isn't in the drugs most people take today — semaglutide and tirzepatide are engineered from the human GLP-1 sequence. But the Gila monster proved the whole thing was possible. It showed that a GLP-1 drug could work, and everything since has been built on that.
For nearly two decades after that, these medications did quiet, unglamorous work treating type 2 diabetes while almost no one outside of endocrinology paid attention.
What COVID changed
Dr. Rocio Salas-Whalen, an endocrinologist who wrote a book called Weightless, makes an observation about this that I keep coming back to.
Before the pandemic, obesity was widely treated as a someday problem — a risk factor for things that might hurt you in twenty years. Heart disease. Diabetes. Stroke. Serious, but distant. Easy to put off.
COVID collapsed that timeline. Almost overnight, obesity became one of the strongest predictors of whether the virus would put you in a hospital bed or kill you that month. That part is not interpretation. The CDC and study after study confirmed obesity as a major, independent risk factor for severe COVID, hospitalization, and death.
When a risk moves from someday to right now, people act. Prescriptions climbed sharply. The version approved specifically for weight loss arrived in 2021. And the explosion everyone remembers followed from there.
Which is worth knowing, because it reframes the whole thing. These aren't a fad that fell out of the sky. They're a long-established class of medicine that a global emergency pushed into the center of our lives.
Obesity is a medical condition, not a character defect
This is the most important thing in this post, and it's the belief most of us have been most thoroughly trained to get wrong.
We've been taught our entire lives that body weight is a matter of willpower. Eat less, move more, and if you can't hold that line, the failure belongs to you. That idea is so deeply embedded in how we all talk that most people have never once stopped to question it.
The medical understanding has moved on, and for good reason. Obesity is a chronic, complex medical condition — shaped by genetics, hormones, brain chemistry, family history, sleep, stress, certain medications, socioeconomic circumstances, and the food environment we all live inside. It is not a shortage of discipline.
Some of the physicians doing the most careful work in this field have even changed how they say it: a person has obesity, the way a person has asthma or high blood pressure. Something you have. Not something you are.
This changes what a GLP-1 even is. If weight is purely a matter of willpower, then a medication looks like a shortcut around work you were supposed to grind through. But if weight is substantially biological, then a medication that acts on that biology is simply treatment — the same way insulin is treatment, the same way thyroid medication is treatment. We don't tell someone with high blood pressure that they just need to want it more.
None of this means our choices stop mattering. There is an enormous amount that is genuinely within our control, and most of my work lives right there. Both things are true at the same time, and the honesty this subject deserves means holding both.
What these medications actually do
Calling them appetite suppressants captures maybe a quarter of what's happening. They work on four systems at once.
They steady your blood sugar. When blood sugar rises after a meal, a GLP-1 signals your pancreas to release insulin, which moves that sugar out of your blood and into your cells for energy. It does this mainly when your blood sugar is actually elevated, which matters for safety. At the same time it lowers glucagon, a hormone that tells your liver to release more sugar. It works both sides of the equation.
They slow your stomach. Food empties more slowly, so it stays with you longer. This is a large part of why people feel full sooner and stay full — and it's also behind most of the common side effects, which I cover in detail in Part 2.
They increase satiety. Satiety is just the feeling of having had enough. These medications turn that signal up, so less food genuinely feels like enough.
They quiet food noise. This is the one people describe with the most emotion, and the one the before-and-after photos completely miss.
Food noise is the constant background hum about food. What to eat, when to eat, what you already ate, what you shouldn't have eaten, the pull toward the kitchen that has nothing to do with being hungry. For a lot of people it runs all day, every day, for decades.
These medications turn that volume down. It happens in the reward circuitry of the brain — the same wiring involved in pleasure and motivation, driven by dopamine. GLP-1 receptors sit right in that circuitry, and when the medication quiets the reward signal that drives you toward food, the noise fades with it.
For someone who has spent a lifetime negotiating with their own brain about food, where every meal is a decision and every craving is a small battle, having that noise go quiet is not a cosmetic change. It's the removal of something heavy they have been carrying since childhood.
And that quiet is what makes everything else possible. It is very hard to build strength, or learn to eat in a way that nourishes you, or establish anything that lasts, while you are spending most of your energy just white-knuckling through the day.
That same reward circuitry comes back in Part 2, because it's also behind a side effect almost nobody is warned about.
The names, and what they actually do
The naming is where most of the confusion lives. Most of these medications come in pairs — the same medicine, two brand names, two different jobs. What separates them is which gut hormones they mimic, so it helps to know what those hormones do.
GLP-1 is the one we've been talking about: it manages blood sugar, slows the stomach, and creates fullness.
GIP is a second gut hormone released when you eat. It also helps regulate insulin and how your body handles fat and sugar. On its own its role is complicated, but paired with GLP-1 it appears to improve blood sugar control and add to weight loss, and it may ease nausea.
Glucagon is a third one, and it does something different. It tells your body to burn stored energy — raising your metabolic rate and pushing your body to break down fat. On its own glucagon would raise blood sugar, but combined with GLP-1, which lowers it, the net effect leans toward burning more energy.
That's what each hormone does. The medications differ in which ones they mimic.
Semaglutide works on GLP-1 alone. It's sold as Ozempic for type 2 diabetes and as Wegovy, at a higher dose, for weight management. There's also Rybelsus, an oral form for diabetes. Semaglutide is the one with the landmark heart data: a major trial found it reduced heart attacks and strokes by about 20% in people at high cardiovascular risk. That's part of why many doctors still reach for semaglutide first when someone's heart is the primary concern.
Tirzepatide works on two hormones — GLP-1 and GIP. It's sold as Mounjaro for diabetes and Zepbound for weight management. That second mechanism is part of why it tends to produce more weight loss on average. In a head-to-head trial, tirzepatide produced about 20% average weight loss compared to semaglutide's roughly 14%.
Liraglutide works on GLP-1 alone and is the older option, taken daily rather than weekly. It's sold as Victoza and Saxenda, and it produces less weight loss, so you hear about it less now.
Retatrutide works on all three — GLP-1, GIP, and glucagon. That third mechanism, the one that pushes your body to burn stored fat, is part of why its trial results have been so dramatic: around 28% average weight loss, approaching what we see with bariatric surgery. It is also not approved. Not by the FDA, not anywhere in the world, for anything. It's still completing the clinical trials that determine whether it's safe and how it should be dosed. I wrote about it in my peptides post, and I come back to it in Part 2, because what's happening around it right now is worth understanding.
One thing I want to be clear about: these are not competitors where one simply wins. They're a toolkit. Tirzepatide tends to produce more weight loss. Semaglutide carries the proven cardiovascular benefit. The right medication depends entirely on the person and their history, and that's a conversation for a doctor who knows both.
Diabetes versus weight loss. People sometimes hear that a diabetes drug is being "used for weight loss" and assume something improper is happening. That isn't what's going on. It's the same molecule, at a different dose, approved for a different purpose. When it's prescribed for type 2 diabetes, the target is blood sugar, and weight loss is a welcome side effect. When it's prescribed for weight management, the target is body weight and metabolic health, usually at a higher dose. You do not need a diabetes diagnosis to qualify for the weight-management versions.
What they can do
The benefits are real and, by the standards of anything that came before, remarkable.
Beyond substantial weight loss, these medications improve blood sugar, insulin sensitivity, blood pressure, and cholesterol. Semaglutide has demonstrated genuine cardiovascular protection. For women with PCOS or insulin resistance, they can steady things in ways that years of dieting never did. Researchers are actively studying benefits well beyond weight, in areas ranging from the liver to the brain, though most of that work is still early.
For the right person, life-changing is not an overstatement. And I would never want my caution about anything in Part 2 to talk someone out of a medication that could genuinely give them their health back.
What they can't do
They do not work like magic for everyone, and this is the part that matters most if you or someone you love has carried a lot of weight for a long time.
The headline numbers are averages, and averages hide an enormous amount. Some people are strong responders. Roughly one in ten lose very little.
And the people least likely to respond dramatically are often those with the most advanced, longest-standing obesity — which is precisely the group that was underrepresented in the trials that produced those famous numbers. The average participant in those studies had far less weight to lose than someone who has been severely obese for decades.
So if you're on one of these medications and the results you were promised never arrived, I want to say this plainly: it is not because you failed. Sometimes it is biology. Sometimes it's that the research was never really measuring people like you. And sometimes — often, actually — it's the dose, which is a real and fixable thing, and one of the first things I cover in Part 2.
A plateau is not the drug quitting on you, either. It's usually your body settling at a new set point.
And a "modest" result is still a real one. A 10 to 15% loss meaningfully improves blood sugar, blood pressure, joint pain, and long-term risk. We have been trained to see anything short of dramatic as nothing at all. That training is wrong.
Who these medications aren't for
These are real drugs with real risks, and a good provider screens for all of this before writing a prescription.
Thyroid cancer history. These carry the FDA's strongest warning, called a boxed warning, because in animal studies they were linked to a rare thyroid tumor. If you have a personal or family history of medullary thyroid cancer — an uncommon type — or a genetic syndrome called MEN2, these medications are not for you.
The nuance here matters, because this is one of the most misunderstood risks and it frightens people unnecessarily. There are several kinds of thyroid cancer, and this warning applies to only one of them: medullary, which makes up only about 3 to 4% of thyroid cancers. The far more common types — papillary and follicular — are not contraindications, and the current human evidence does not show that these medications cause them. The warning itself comes from rodent studies, at doses far higher than what people take, and it has never been demonstrated in humans. So a family history of the common thyroid cancers is not the same as a family history of medullary, and it's worth knowing the difference before you let a headline scare you off. Your family history is something a good doctor asks about before you start.
Pancreatitis. A history of pancreatitis is a reason to pause and consider a different approach.
Gallbladder problems. Rapid weight loss of any kind raises the risk of gallstones, so gallbladder issues are more common on these medications.
Gastroparesis. If your stomach already empties too slowly, a medication designed to slow it further can make things worse.
Pregnancy, and trying to conceive. This one deserves more attention than it gets, and it's the piece I most want the women reading this to know.
These medications are not safe in pregnancy. And they can quietly make pregnancy more likely.
Losing weight and improving insulin sensitivity can restart ovulation in women who believed they couldn't conceive — particularly women with PCOS. That's where all the "Ozempic baby" stories come from. On top of that, tirzepatide can make oral birth control less reliable; the manufacturer advises backup or non-oral contraception for four weeks after starting the medication and after every dose increase.
Put those two facts together and you get women becoming unexpectedly pregnant on a medication they can't safely continue. Current guidance is to stop these drugs one to two months before trying to conceive, and to stop immediately and call your provider if you find out you're pregnant.
If you are a woman of reproductive age, this should have been said to you out loud by whoever prescribed your medication.
The part that comes next
That's what these drugs are. A copy of a hormone you already make, engineered to last. A real advance in medicine. A genuine gift for some people, more complicated for others.
But the medication is only half of the story, and honestly it's the easier half.
What determines whether someone comes out of this healthier — rather than simply smaller — is the care around it. The dose. The protein. The muscle. The monitoring. Whether anyone is actually watching what's happening inside your body, or whether they're just watching the scale go down.
That care is being skipped, at scale, right now. And most people have no idea what they should be asking for.
That's Part 2.
Nothing here is medical advice. I'm a massage therapist and wellness educator sharing what I've learned from the research. Please make decisions about your body with a provider who actually knows you.
Sources include: FDA approval and labeling history for exenatide, liraglutide, semaglutide, and tirzepatide; Dr. John Eng's 1992 discovery of exendin-4 and the DPP-4-driven half-life of native GLP-1; CDC and peer-reviewed research on obesity as an independent risk factor for severe COVID-19; the SELECT cardiovascular outcomes trial and the SURMOUNT-5 head-to-head weight loss trial; peer-reviewed literature on GLP-1, GIP, and glucagon receptor mechanisms; the Clayman Thyroid Center white paper and Cleveland Clinic guidance on GLP-1s and thyroid cancer subtypes; Yale Medicine and peer-reviewed literature on individual variation and non-response; FDA prescribing information on pancreatitis, gallbladder, gastroparesis, contraception, and pregnancy; and Dr. Rocio Salas-Whalen's Weightless. My peptides post covers compounding, sourcing, and the grey market in depth.